Stevanato Group (NYSE:STVN) Shares Gap Up – Here’s What Happened
by Renee Jackson · The Cerbat GemStevanato Group S.p.A. (NYSE:STVN – Get Free Report)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at €17.33, but opened at €18.25. Stevanato Group shares last traded at €18.21, with a volume of 24,427 shares changing hands.
Wall Street Analysts Forecast Growth
STVN has been the topic of several recent analyst reports. Jefferies Financial Group set a $17.50 target price on shares of Stevanato Group in a research note on Tuesday, February 10th. Citigroup cut their price target on Stevanato Group from $32.00 to $26.00 and set a “buy” rating for the company in a report on Thursday, March 5th. Morgan Stanley cut their price target on Stevanato Group from $24.00 to $19.00 and set an “equal weight” rating for the company in a report on Friday, March 6th. KeyCorp cut their price target on Stevanato Group from $37.00 to $32.00 and set an “overweight” rating for the company in a report on Thursday, March 5th. Finally, Wall Street Zen cut Stevanato Group from a “buy” rating to a “hold” rating in a report on Saturday, February 14th. Three investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold”.
Read Our Latest Report on Stevanato Group
Stevanato Group Price Performance
The stock has a market capitalization of $5.43 billion, a P/E ratio of 30.42, a PEG ratio of 1.60 and a beta of 0.75. The company has a current ratio of 1.63, a quick ratio of 1.11 and a debt-to-equity ratio of 0.21. The company has a fifty day simple moving average of €15.57 and a two-hundred day simple moving average of €18.23.
Stevanato Group (NYSE:STVN – Get Free Report) last announced its quarterly earnings data on Friday, May 8th. The company reported €0.11 earnings per share for the quarter, missing the consensus estimate of €0.12 by (€0.01). The firm had revenue of €273.57 million for the quarter. Stevanato Group had a return on equity of 10.27% and a net margin of 11.76%.The company’s revenue was up 6.6% on a year-over-year basis. During the same period in the prior year, the company earned $0.10 earnings per share. Sell-side analysts expect that Stevanato Group S.p.A. will post 0.68 EPS for the current fiscal year.
Institutional Trading of Stevanato Group
Several institutional investors and hedge funds have recently added to or reduced their stakes in STVN. Royal Bank of Canada raised its holdings in Stevanato Group by 10.8% during the 1st quarter. Royal Bank of Canada now owns 437,284 shares of the company’s stock worth $8,930,000 after purchasing an additional 42,731 shares during the last quarter. Sei Investments Co. raised its holdings in Stevanato Group by 16.9% during the 2nd quarter. Sei Investments Co. now owns 231,244 shares of the company’s stock worth $5,649,000 after purchasing an additional 33,419 shares during the last quarter. Raymond James Financial Inc. increased its stake in shares of Stevanato Group by 21.2% in the 2nd quarter. Raymond James Financial Inc. now owns 567,803 shares of the company’s stock valued at $13,871,000 after acquiring an additional 99,328 shares during the last quarter. Ameriprise Financial Inc. increased its stake in shares of Stevanato Group by 14.2% in the 2nd quarter. Ameriprise Financial Inc. now owns 708,821 shares of the company’s stock valued at $17,316,000 after acquiring an additional 87,942 shares during the last quarter. Finally, Bamco Inc. NY increased its stake in shares of Stevanato Group by 2.1% in the 2nd quarter. Bamco Inc. NY now owns 1,888,050 shares of the company’s stock valued at $46,125,000 after acquiring an additional 39,528 shares during the last quarter.
About Stevanato Group
Stevanato Group is a global provider of primary packaging solutions and related services for the pharmaceutical and biotech industries. The company specializes in the design, development and manufacturing of glass drug containers such as vials, cartridges and pre-fillable syringes, as well as advanced inspection systems and assembly equipment. Its integrated offerings cover the entire packaging supply chain, from component production to bespoke filling lines and serialization technology.
In addition to its core glass business, Stevanato Group delivers engineering services and process validation support to pharmaceutical customers.